Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GREGORY HACHIGIAN

Allopathic & Osteopathic Physicians Emergency Medicine

NPI
1558342022
CMS profile
777601
Location
SACRAMENTO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$108.33

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $108.33 1

By paying entity

PY2022 · entire year · sorted by reported total

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GREGORY HACHIGIAN

NPI 1558342022 · CMS profile ID 777601

Allopathic & Osteopathic Physicians / Emergency Medicine

SACRAMENTO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1558342022?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GREGORY HACHIGIAN, NPI 1558342022, CMS profile ID 777601. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1558342022?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). GREGORY HACHIGIAN, NPI 1558342022, CMS profile ID 777601. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1558342022?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
GREGORY HACHIGIAN, NPI 1558342022, CMS profile ID 777601, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1558342022?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $108.33 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Otsuka Pharmaceutical Development & Commercialization, Inc. $108.3307/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 933756527 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2022 $108.33 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2022
Source files and profile matching
Source files
Dataset page · Bulk file · PY2022
Generated from
OP_DTL_GNRL_PGYR2022_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

This record has limited reported data across the program years shown and is not featured in search indexes. The records below are complete; see the methodology for how featured pages are determined.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $281,766.82 21
PY2023 Principal investigator $1,564,117.66 137
PY2022 Principal investigator $4,578,170.79 303
PY2021 Principal investigator $4,478,036.63 220
PY2020 Principal investigator $6,027.12 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

137 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ModernaTX, Inc. $536.25 12/20/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 1041839257
Principal investigator 1 PFIZER INC. $234.80 12/11/2023 Non-covered Recipient Entity
Benchmark Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046073021
Principal investigator 1 PFIZER INC. $15.04 12/09/2023 Non-covered Recipient Entity
Benchmark Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046267723
Principal investigator 1 ModernaTX, Inc. $178.75 12/04/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 1041839263
Principal investigator 1 PFIZER INC. $403.92 11/30/2023 Non-covered Recipient Entity
Benchmark Research Sacramento Arden Way
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046074403
Principal investigator 1 PFIZER INC. $41,800.00 10/24/2023 Non-covered Recipient Entity
LSB Research Group LLC dba Benchmark Research
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045866785
Principal investigator 1 ModernaTX, Inc. $15,150.85 10/18/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 1041838329
Principal investigator 1 ModernaTX, Inc. $650.00 10/13/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 1041837297
Principal investigator 1 ModernaTX, Inc. $2,850.00 10/04/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 1041837291
Principal investigator 1 ModernaTX, Inc. $1,153.75 10/02/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 1041838371
Principal investigator 1 Janssen Research & Development, LLC $9,698.00 09/26/2023 Non-covered Recipient Entity
Lsb Rsrch Group Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 986130767
Principal investigator 1 ModernaTX, Inc. $130.00 09/13/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 1041837207
Principal investigator 1 ModernaTX, Inc. $598.00 09/13/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 1041837845
Principal investigator 1 ModernaTX, Inc. $35,690.00 09/13/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 1041837857
Principal investigator 1 ModernaTX, Inc. $757.55 09/06/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Lyophilized Cytomegalovirus Vaccine mRNA-1647 in Healthy Adults No dispute reported 06/30/2026 1041837903
Principal investigator 1 ModernaTX, Inc. $1,200.00 09/06/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Lyophilized Cytomegalovirus Vaccine mRNA-1647 in Healthy Adults No dispute reported 06/30/2026 1041837909
Principal investigator 1 ModernaTX, Inc. $2,000.00 09/01/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 1041837171
Principal investigator 1 ModernaTX, Inc. $4,500.00 09/01/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 1041837177
Principal investigator 1 ModernaTX, Inc. $110,215.30 08/30/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 1041837695
Principal investigator 1 PFIZER INC. $2,259.20 08/24/2023 Non-covered Recipient Entity
LSB Research Group LLC dba Benchmark Research
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045906899
Principal investigator 1 PFIZER INC. $32,311.35 08/23/2023 Non-covered Recipient Entity
LSB Research Group LLC dba Benchmark Research
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045902273
Principal investigator 1 ModernaTX, Inc. $1,471.60 08/04/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 1041837689
Principal investigator 1 Janssen Research & Development, LLC $3,142.00 08/02/2023 Non-covered Recipient Entity
Lsb Rsrch Group Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 986130769
Principal investigator 1 Janssen Research & Development, LLC $8,700.00 07/26/2023 Non-covered Recipient Entity
Lsb Rsrch Group Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 986130765
Principal investigator 1 ModernaTX, Inc. $260.00 07/19/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 1041836545
Principal investigator 1 Janssen Research & Development, LLC $3,128.00 07/17/2023 Non-covered Recipient Entity
Lsb Rsrch Group Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 986130771
Principal investigator 1 PFIZER INC. $17,977.95 07/06/2023 Non-covered Recipient Entity
LSB Research Group LLC dba Benchmark Research
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045905699
Principal investigator 1 ModernaTX, Inc. $3,315.00 06/28/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 1041837677
Principal investigator 1 Janssen Research & Development, LLC $195.00 06/26/2023 Non-covered Recipient Entity
Lsb Rsrch Group Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 986130759
Principal investigator 1 Novavax Inc $2,006.00 06/20/2023 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055262959
Principal investigator 1 Novavax Inc $1,612.00 06/13/2023 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055260977
Principal investigator 1 Novavax Inc $1,612.00 06/08/2023 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055261943
Principal investigator 1 PFIZER INC. $9,879.80 06/08/2023 Non-covered Recipient Entity
LSB Research Group LLC dba Benchmark Research
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045905713
Principal investigator 1 Novavax Inc $4,574.00 05/30/2023 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055262955
Principal investigator 1 PFIZER INC. $28,921.05 05/26/2023 Non-covered Recipient Entity
LSB Research Group LLC dba Benchmark Research
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045908689
Principal investigator 1 Janssen Research & Development, LLC $1,453.00 05/24/2023 Non-covered Recipient Entity
Lsb Rsrch Group Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 986130757
Principal investigator 1 Novavax Inc $14,508.00 05/24/2023 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055262957
Principal investigator 1 ModernaTX, Inc. $710.00 05/17/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 1041836413
Principal investigator 1 Novavax Inc $7,888.00 05/16/2023 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055260975
Principal investigator 1 Novavax Inc $7,546.00 05/09/2023 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055264905
Principal investigator 1 ModernaTX, Inc. $727.35 05/03/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 1041837503
Principal investigator 1 Novavax Inc $786.00 05/03/2023 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055260979
Principal investigator 1 ModernaTX, Inc. $5,318.95 05/01/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 1041837039
Principal investigator 1 ModernaTX, Inc. $375.00 05/01/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041838721
Principal investigator 1 Novavax Inc $9,210.00 04/26/2023 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055260971
Principal investigator 1 Janssen Research & Development, LLC $2,730.00 04/21/2023 Non-covered Recipient Entity
Lsb Rsrch Group Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 986130755
Principal investigator 1 ModernaTX, Inc. $2,704.00 04/19/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 1041837033
Principal investigator 1 Novavax Inc $7,598.00 04/18/2023 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055259967
Principal investigator 1 ModernaTX, Inc. $74,007.05 04/14/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 1041837011
Principal investigator 1 ModernaTX, Inc. $28,866.50 04/14/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 1041837017
Principal investigator 1 ModernaTX, Inc. $75,766.60 04/14/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 1041837023
Principal investigator 1 ModernaTX, Inc. $48,976.20 04/14/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 1041837029
Principal investigator 1 ModernaTX, Inc. $1,500.00 04/07/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Lyophilized Cytomegalovirus Vaccine mRNA-1647 in Healthy Adults No dispute reported 06/30/2026 1041836437
Principal investigator 1 ModernaTX, Inc. $727.35 04/07/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 1041837005
Principal investigator 1 Novavax Inc $4,978.00 04/04/2023 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055263901
Principal investigator 1 Novavax Inc $3,930.00 03/29/2023 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055260973
Principal investigator 1 Novavax Inc $2,090.00 03/29/2023 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055265933
Principal investigator 1 Novavax Inc $2,620.00 03/24/2023 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055259001
Principal investigator 1 Novavax Inc $1,705.00 03/24/2023 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055262953
Principal investigator 1 PFIZER INC. $22,457.15 03/24/2023 Non-covered Recipient Entity
LSB Research Group LLC dba Benchmark Research
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045909325
Principal investigator 1 ModernaTX, Inc. $3,276.00 03/22/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 1041837001
Principal investigator 1 Novavax Inc $2,620.00 03/21/2023 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055264903
Principal investigator 1 Janssen Research & Development, LLC $7,215.00 03/20/2023 Non-covered Recipient Entity
Lsb Rsrch Group Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 986130743
Principal investigator 1 ModernaTX, Inc. $650.00 03/17/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 1041836405
Principal investigator 1 ModernaTX, Inc. $12,035.00 03/17/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041837131
Principal investigator 1 ModernaTX, Inc. $75.00 03/15/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 1041836401
Principal investigator 1 Novavax Inc $6,812.00 03/15/2023 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055261941
Principal investigator 1 ModernaTX, Inc. $2,490.00 03/08/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041837125
Principal investigator 1 Novavax Inc $8,287.00 03/08/2023 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055259965
Principal investigator 1 Novavax Inc $2,096.00 03/08/2023 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055263899
Principal investigator 1 ModernaTX, Inc. $75.00 03/01/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 1041836393
Principal investigator 1 ModernaTX, Inc. $2,909.40 03/01/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 1041836993
Principal investigator 1 ModernaTX, Inc. $32.50 03/01/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041837113
Principal investigator 1 ModernaTX, Inc. $2,905.00 03/01/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041837117
Principal investigator 1 Novavax Inc $4,761.00 02/28/2023 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055262951
Principal investigator 1 ModernaTX, Inc. $2,600.00 02/24/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 1041836381
Principal investigator 1 ModernaTX, Inc. $75.00 02/24/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 1041836387
Principal investigator 1 ModernaTX, Inc. $999.70 02/24/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 1041836981
Principal investigator 1 ModernaTX, Inc. $2,909.40 02/24/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 1041836987
Principal investigator 1 Janssen Research & Development, LLC $30,950.00 02/22/2023 Non-covered Recipient Entity
Lsb Rsrch Group Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 986130741
Principal investigator 1 ModernaTX, Inc. $1,350.00 02/22/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 1041836369
Principal investigator 1 ModernaTX, Inc. $520.00 02/22/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 1041836375
Principal investigator 1 ModernaTX, Inc. $27,729.00 02/22/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 1041836969
Principal investigator 1 ModernaTX, Inc. $3,636.75 02/22/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 1041836977
Principal investigator 1 Novavax Inc $7,601.00 02/22/2023 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055263897
Principal investigator 1 Novavax Inc $9,222.00 02/22/2023 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055265931
Principal investigator 1 Novavax Inc $7,074.00 02/16/2023 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055261939
Principal investigator 1 Novavax Inc $12,061.00 02/16/2023 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055264901
Principal investigator 1 ModernaTX, Inc. $2,550.00 02/15/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 1041836363
Principal investigator 1 ModernaTX, Inc. $3,677.70 02/15/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 1041836965
Principal investigator 1 PFIZER INC. $1,140.00 02/15/2023 Non-covered Recipient Entity
LSB Research Group LLC dba Benchmark Research
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045901847
Principal investigator 1 ModernaTX, Inc. $625.00 02/10/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041836431
Principal investigator 1 ModernaTX, Inc. $26,211.25 02/10/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041837107
Principal investigator 1 Novavax Inc $2,358.00 02/09/2023 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055259963
Principal investigator 1 Novavax Inc $65,935.20 02/09/2023 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055260981
Principal investigator 1 ModernaTX, Inc. $650.00 02/08/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 1041836357
Principal investigator 1 ModernaTX, Inc. $525.00 02/03/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 1041836333
Principal investigator 1 ModernaTX, Inc. $975.00 02/03/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 1041836339
Principal investigator 1 ModernaTX, Inc. $1,950.00 02/03/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 1041836345
Principal investigator 1 ModernaTX, Inc. $450.00 02/03/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 1041836351
Principal investigator 1 ModernaTX, Inc. $10,000.00 02/03/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041836419
Principal investigator 1 ModernaTX, Inc. $12,900.00 02/03/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041836425
Principal investigator 1 ModernaTX, Inc. $46,677.80 02/03/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 1041836935
Principal investigator 1 ModernaTX, Inc. $8,728.20 02/03/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 1041836941
Principal investigator 1 ModernaTX, Inc. $11,458.85 02/03/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 1041836947
Principal investigator 1 ModernaTX, Inc. $5,005.00 02/03/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 1041836953
Principal investigator 1 ModernaTX, Inc. $29,133.65 02/03/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 1041836959
Principal investigator 1 ModernaTX, Inc. $625.00 02/03/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041837089
Principal investigator 1 ModernaTX, Inc. $43,436.25 02/03/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041837095
Principal investigator 1 ModernaTX, Inc. $17,935.00 02/03/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041837101
Principal investigator 1 ModernaTX, Inc. $3,500.00 02/03/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041838715
Principal investigator 1 Novavax Inc $11,692.00 02/02/2023 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055258999
Principal investigator 1 Novavax Inc $6,760.00 02/02/2023 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055260969
Principal investigator 1 ModernaTX, Inc. $1,450.00 02/01/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 1041836327
Principal investigator 1 ModernaTX, Inc. $4,621.50 02/01/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 1041836929
Principal investigator 1 ModernaTX, Inc. $34,983.75 02/01/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041837083
Principal investigator 1 ModernaTX, Inc. $760.00 01/27/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 1041836321
Principal investigator 1 ModernaTX, Inc. $434.25 01/27/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041837079
Principal investigator 1 Janssen Research & Development, LLC $1,865.00 01/25/2023 Non-covered Recipient Entity
Lsb Rsrch Group Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 986130745
Principal investigator 1 Novavax Inc $4,716.00 01/25/2023 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055264899
Principal investigator 1 Novavax Inc $11,537.00 01/20/2023 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055262949
Principal investigator 1 ModernaTX, Inc. $806.62 01/18/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041837061
Principal investigator 1 ModernaTX, Inc. $26,668.75 01/18/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041837069
Principal investigator 1 ModernaTX, Inc. $15,048.75 01/18/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041837073
Principal investigator 1 ModernaTX, Inc. $8,268.00 01/13/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 1041836923
Principal investigator 1 ModernaTX, Inc. $2,338.88 01/13/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041837043
Principal investigator 1 ModernaTX, Inc. $8,079.75 01/13/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041837049
Principal investigator 1 ModernaTX, Inc. $16,146.00 01/13/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041837055
Principal investigator 1 ModernaTX, Inc. $750.00 01/11/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 1041836315
Principal investigator 1 PFIZER INC. $10,260.00 01/11/2023 Non-covered Recipient Entity
LSB Research Group LLC dba Benchmark Research
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045899979
Principal investigator 1 Novavax Inc $6,208.00 01/10/2023 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055258997
Principal investigator 1 Novavax Inc $2,830.00 01/10/2023 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055259961
Principal investigator 1 Novavax Inc $7,393.00 01/06/2023 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055258995
Principal investigator 1 Novavax Inc $22,550.00 01/06/2023 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055259959
Principal investigator 1 ModernaTX, Inc. $2,850.00 01/04/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 1041836309
Principal investigator 1 ModernaTX, Inc. $215,881.90 01/04/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 1041836909
Principal investigator 1 ModernaTX, Inc. $1,499.55 01/04/2023 Non-covered Recipient Entity
Benchmark Research - Sacramento - HyperCore - PPDS
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 1041836917